Suscribirse

N-terminal Pro B-type Natriuretic Peptide in the Early Evaluation of Suspected Acute Myocardial Infarction - 25/07/11

Doi : 10.1016/j.amjmed.2011.02.035 
Philip Haaf, MD a, , Cathrin Balmelli, MD a, , Tobias Reichlin, MD a, b, Raphael Twerenbold, MD a, Miriam Reiter, MD a, Julia Meissner, MD a, Nora Schaub, MD a, Claudia Stelzig, MSc a, Michael Freese, RN a, Patricia Paniz, MD a, Christophe Meune, MD, PhD a, c, Beatrice Drexler, MD a, Heike Freidank, MD d, Katrin Winkler, MD e, f, Willibald Hochholzer, MD a, g, Christian Mueller, MD, FESC a, b,
a Department of Internal Medicine, University Hospital, Basel, Switzerland 
b Department of Cardiology, University Hospital, Basel, Switzerland 
c Cardiology Department, Paris Descartes University, Cochin Hospital, APHP, Paris, France 
d Department of Laboratory Medicine, University Hospital, Basel, Switzerland 
e Servicio de Pneumologia, Hospital del Mar - IMIM UPF, CIBERES, ISC III, Barcelona, Spain 
f Servicio de Urgencias, Hospital del Mar - IMIM UPF, CIBERES, ISC III, Barcelona, Spain 
g TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 

Requests for reprints should be addressed to Christian Mueller, MD, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, Basel CH-4031, Switzerland

Abstract

Background

Myocardial ischemia is a strong trigger of N-terminal pro-B-type natriuretic peptide (NT-proBNP) release. As ischemia precedes necrosis in acute myocardial infarction, we hypothesized that NT-proBNP might be useful in the early diagnosis and risk stratification of patients with suspected acute myocardial infarction.

Methods

In a prospective multicenter study, NT-proBNP was measured at presentation in 658 consecutive patients with acute chest pain. The final diagnosis was adjudicated by 2 independent cardiologists. Patients were followed long term regarding mortality.

Results

Acute myocardial infarction was the adjudicated final diagnosis in 117 patients (18%). NT-proBNP levels at presentation were significantly higher in acute myocardial infarction as compared with patients with other final diagnoses (median 886 pg/mL vs 135 pg/mL, P <.001). The diagnostic accuracy of NT-proBNP for acute myocardial infarction as quantified by the area under the receiver operating characteristic curve (AUC) was 0.79 (95% confidence interval [CI], 0.75-0.83). When added to cardiac troponin T, NT-proBNP significantly increased the AUC from 0.89 (95% CI, 0.84-0.93) to 0.91 (95% CI, 0.88-0.94; P=.033). Cumulative 24-month mortality rates were 0% in the first, 1.3% in the second, 8.3% in the third, and 23.3% in the fourth quartile of NT-proBNP (P <.001). NT-proBNP (AUC 0.85, 95% CI, 0.81-0.89) predicted all-cause mortality independently of and more accurately than both cardiac troponin T (AUC 0.66, 95% CI, 0.58-0.74; P <.001) and the Thrombolysis in Myocardial Infarction risk score (AUC 0.79, 95% CI, 0.74-0.84; P <.001). Net reclassification improvement (Thrombolysis in Myocardial Infarction vs additionally NT-proBNP) was 0.188 (P <.009), and integrated discrimination improvement was 0.100 (P <.001).

Conclusions

Use of NT-proBNP improves the early diagnosis and risk stratification of patients with suspected acute myocardial infarction.

El texto completo de este artículo está disponible en PDF.

Keywords : Acute chest pain, Early diagnosis, NT-proBNP, Risk stratification


Esquema


 Funding: The study was supported by research grants from the Swiss National Science Foundation (PP00B-102853), the Swiss Heart Foundation, Roche, and the Department of Internal Medicine, University Hospital Basel.
 Conflict of Interest: We disclose that Dr. Mueller has received research support from the Swiss National Science Foundation (PP00B-102853), the Swiss Heart Foundation, the Stanley Thomas Johnson Foundation, Abbott, ALERE, Brahms, Nanosphere, Roche, Siemens, and the Department of Internal Medicine, University Hospital Basel, as well as speaker honoraria from Abbott, ALERE, Brahms, Roche, and Siemens. Dr. Reichlin has received research grants from the University of Basel and the Department of Internal Medicine, University Hospital Basel, as well as speaker honoraria from Brahms and Roche. Dr. Meune was supported by a grant from the Freie Akademische Gesellschaft Basel (FAG). All other authors declare that they have no conflict of interest.
 Authorship: The authors designed the study, gathered and analyzed the data, vouch for the data and analysis, wrote the paper, and decided to publish. The sponsors had no role in designing or conducting the study and no role in gathering or analyzing the data or writing the manuscript. All authors had access to the data and a role in writing the manuscript.


© 2011  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 124 - N° 8

P. 731-739 - août 2011 Regresar al número
Artículo precedente Artículo precedente
  • Plasma Interleukin-10 Levels and Adverse Outcomes in Acute Coronary Syndrome
  • Erdal Cavusoglu, Jonathan D. Marmur, Mohammad R. Hojjati, Vineet Chopra, Mitul Butala, Rakesh Subnani, Mohammad S. Huda, Sunitha Yanamadala, Cyril Ruwende, Calvin Eng, David J. Pinsky
| Artículo siguiente Artículo siguiente
  • Trends in Outpatient Transthoracic Echocardiography: Impact of Appropriateness Criteria Publication
  • Ali R. Rahimi, Meghan York, Neil Gheewala, Larry Markson, Thomas H. Hauser, Warren J. Manning

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.